SHANGHAI – Hua Medicine Ltd. released the top-line results from the phase II trial of HMS5552, a fourth-generation glucokinase activator (GKA) used as a single drug to treat type 2 diabetes patients in China. The Shanghai-based biotech said the study shows statistically significant efficacy data, as well as an excellent tolerability and safety profile, with low risk of hypoglycemia or other side effects common in diabetes treatments.